Terebellum Announces Partnership with NeurosolvTherapeutics

Terebellum has announced a contractual partnership with NeurosolvTherapeutics, bringing its full suite of capabilities to support the launch of Perineline™.

Perineline™ is a new patented two-part therapy for spinal cord injuries developed by NeurosolvTherapeutics that has now attained EMA Orphan Designation and is expected to revolutionise the therapeutic treatment

Terebellum’s services will include strategic guidance in the pre-commercialisation stage, market access expertise, and supply chain logistics including distribution and fulfilment.

Craig Caceci, Managing Director, Terebellum, says, “Our dedicated team of highly experienced market access professionals look forward to working closely with NeursolvTherapeutics in a successful product launch that establishes optimal pricing and ensures seamless product access for patients with spinal cord injuries. This is an exciting time to be introducing a game-changing therapeutic treatment.”

Aidan Lynch, chairman and chief executive officer, NeursolvTherapeutics, says,“We are excited to work with Terebellum to bring Perineline™ to market globally, to allow us to proliferate and enable ethically controlled patient access under spinal cord trauma consultants.”

“The many years of pioneering and trailblazing research developed by our Founders Ros Lynch and Aidan Lynch and Scientific Chair Dr. Jessica Kwok are bringing seismic change to the prospects for recovery of spinal cord injury patients.

“Terebellum’s consultative business model and collaborative approach enables us to take advantage of their thorough expertise and knowledge which are critical to the launch planning and commercialisation of Perineline™.

“At every step of the way, we know that we can rely upon Terebellum for key strategic insights throughout the implementation process.”